Full View

Population pharmacokinetics of piperacillin in nonobese, obese, and morbidly obese critically ill patients

AS Alobaid, SC Wallis, P Jarrett, T Starr… - Antimicrobial agents …, 2017 - Am Soc Microbiol
The treatment of infections in critically ill obese and morbidly obese patients is challenging
because of the combined physiological changes that result from obesity and critical illness …
被引用次数：72 相关文章

Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients

A Alobaid, S Wallis, P Jarrett, T Starr… - Antimicrobial Agents …, 2017 - hal.umontpellier.fr
The treatment of infections in critically ill obese and morbidly obese patients is challenging
because of the combined physiological changes that result from obesity and critical illness …
[PDF] monash.edu

[PDF][PDF] Population pharmacokinetics of piperacillin in nonobese, obese, and morbidly obese critically ill patients

AS Alobaid, SC Wallis, P Jarrett, T Starr… - Antimicrob Agents …, 2017 - research.monash.edu
The treatment of infections in critically ill obese and morbidly obese patients is challenging
because of the combined physiological changes that result from obesity and critical illness …
[PDF] core.ac.uk

[PDF][PDF] Population pharmacokinetics of piperacillin in nonobese, obese, and morbidly obese critically ill patients

AS Alobaid, SC Wallis, P Jarrett, T Starr… - Antimicrob Agents …, 2017 - core.ac.uk
The treatment of infections in critically ill obese and morbidly obese patients is challenging
because of the combined physiological changes that result from obesity and critical illness …

Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.

AS Alobaid, SC Wallis, P Jarrett, T Starr… - Antimicrobial Agents …, 2017 - europepmc.org
The treatment of infections in critically ill obese and morbidly obese patients is challenging
because of the combined physiological changes that result from obesity and critical illness …

[引用][C] Population pharmacokinetics of piperacillin in nonobese, obese, and morbidly obese critically ill patients

AS Alobaid, SC Wallis, P Jarrett… - Antimicrobial …, 2017 - espace.library.uq.edu.au
The treatment of infections in critically ill obese and morbidly obese patients is challenging
because of the combined physiological changes that result from obesity and critical illness …

Population pharmacokinetics of piperacillin in nonobese, obese, and morbidly obese critically ill patients

A Alobaid, S Wallis, P Jarrett, T Starr… - Antimicrobial Agents …, 2017 - eprints.qut.edu.au
Free to read on publisher's website The treatment of infections in critically ill obese and
morbidly obese patients is challenging because of the combined physiological changes that …
[HTML] nih.gov

[HTML][HTML] Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients

AS Alobaid, SC Wallis, P Jarrett, T Starr… - Antimicrobial Agents …, 2017 - ncbi.nlm.nih.gov
The treatment of infections in critically ill obese and morbidly obese patients is challenging
because of the combined physiological changes that result from obesity and critical illness …

Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients

AS Alobaid, SC Wallis, P Jarrett… - Antimicrobial …, 2017 - pubmed.ncbi.nlm.nih.gov
The treatment of infections in critically ill obese and morbidly obese patients is challenging
because of the combined physiological changes that result from obesity and critical illness …

Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients

A Alobaid, S Wallis, P Jarrett, T Starr, J Stuart… - Antimicrobial Agents …, 2017 - hal.science
The treatment of infections in critically ill obese and morbidly obese patients is challenging
because of the combined physiological changes that result from obesity and critical illness …